CLOs on the Move


 
Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.janpixbio.com
  • One Broadway, 14th Floor
    Cambridge, MA USA 02142
  • Phone: 617.956.2803

Executives

Name Title Contact Details

Similar Companies

Aspect DV

Aspect DV is a Merrimack, NH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Inipharm

At Inipharm, we`re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm`s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.

Cannabis Science

Cannabis Science is a Colorado Springs, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmexa-Epimmune

Pharmexa-Epimmune Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ZIOPHARM Oncology

ZIOPHARM Oncology is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.